Luke V Selby1, Mindy Sovel1, Daniel D Sjoberg2, Margaret McSweeney3, Damon Douglas4, David R Jones1, Peter T Scardino1, Gerald A Soff5, Nicola Fabbri1, Kent Sepkowitz5, Vivian E Strong6, Inderpal S Sarkaria7. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: strongv@mskcc.org. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Abstract
BACKGROUND: We prospectively evaluated the safety and efficacy of adding preoperative chemoprophylaxis to our institution's operative venous thromboembolism (VTE) prophylaxis policy as part of a physician-led quality improvement initiative. STUDY DESIGN: Patients undergoing major cancer surgery between August 2013 and January 2014 were screened according to service-specific eligibility criteria and targeted to receive preoperative VTE chemoprophylaxis. Bleeding, transfusion, and VTE rates were compared with rates of historical controls who had not received preoperative chemoprophylaxis. RESULTS: The 2,058 eligible patients who underwent operation between August 2013 and January 2014 (post-intervention) were compared with a cohort of 4,960 patients operated on between January 2012 and June 2013, who did not receive preoperative VTE chemoprophylaxis (pre-intervention). In total, 71% of patients in the post-intervention group were screened for eligibility; 82% received preoperative anticoagulation. When compared with the pre-intervention group, the post-intervention group had significantly lower transfusion rates (pre- vs post-intervention, 17% vs 14%; difference 3.5%, 95% CI 1.7% to 5%, p = 0.0003) without significant difference in major bleeding (difference 0.3%, 95% CI -0.1% to 0.7%, p = 0.2). Rates of deep venous thrombosis (1.3% vs 0.2%; difference 1.1%, 95% CI 0.7% to 1.4%, p < 0.0001) and pulmonary embolus (1.0% vs 0.4%; difference 0.6%, 95% CI 0.2% to 1%, p = 0.017) were significantly lower in the post-intervention group. CONCLUSIONS: In patients undergoing major cancer surgery, institution of a single dose of preoperative chemoprophylaxis, as part of a physician-led quality improvement initiative, did not increase bleeding or blood transfusions and was associated with a significant decrease in VTE rates.
BACKGROUND: We prospectively evaluated the safety and efficacy of adding preoperative chemoprophylaxis to our institution's operative venous thromboembolism (VTE) prophylaxis policy as part of a physician-led quality improvement initiative. STUDY DESIGN:Patients undergoing major cancer surgery between August 2013 and January 2014 were screened according to service-specific eligibility criteria and targeted to receive preoperative VTE chemoprophylaxis. Bleeding, transfusion, and VTE rates were compared with rates of historical controls who had not received preoperative chemoprophylaxis. RESULTS: The 2,058 eligible patients who underwent operation between August 2013 and January 2014 (post-intervention) were compared with a cohort of 4,960 patients operated on between January 2012 and June 2013, who did not receive preoperative VTE chemoprophylaxis (pre-intervention). In total, 71% of patients in the post-intervention group were screened for eligibility; 82% received preoperative anticoagulation. When compared with the pre-intervention group, the post-intervention group had significantly lower transfusion rates (pre- vs post-intervention, 17% vs 14%; difference 3.5%, 95% CI 1.7% to 5%, p = 0.0003) without significant difference in major bleeding (difference 0.3%, 95% CI -0.1% to 0.7%, p = 0.2). Rates of deep venous thrombosis (1.3% vs 0.2%; difference 1.1%, 95% CI 0.7% to 1.4%, p < 0.0001) and pulmonary embolus (1.0% vs 0.4%; difference 0.6%, 95% CI 0.2% to 1%, p = 0.017) were significantly lower in the post-intervention group. CONCLUSIONS: In patients undergoing major cancer surgery, institution of a single dose of preoperative chemoprophylaxis, as part of a physician-led quality improvement initiative, did not increase bleeding or blood transfusions and was associated with a significant decrease in VTE rates.
Authors: Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Scott G Louis; Misa Sato; Travis Geraci; Ross Anderson; S David Cho; Philbert Y Van; Jeffrey S Barton; Gordon M Riha; Samantha Underwood; Jerome Differding; Jennifer M Watters; Martin A Schreiber Journal: JAMA Surg Date: 2014-04 Impact factor: 14.766
Authors: Karl Y Bilimoria; Jeanette Chung; Mila H Ju; Elliott R Haut; David J Bentrem; Clifford Y Ko; David W Baker Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544
Authors: Ajay K Kakkar; Giancarlo Agnelli; William Fisher; Daniel George; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Judith Murphy; Francesca Lawson; Alexander G G Turpie Journal: Ann Surg Date: 2014-06 Impact factor: 12.969
Authors: Kenneth M Shermock; Brandyn D Lau; Elliott R Haut; Deborah B Hobson; Valerie S Ganetsky; Peggy S Kraus; Leigh E Efird; Christoph U Lehmann; Brian L Pinto; Patricia A Ross; Michael B Streiff Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: N Alhassan; M Trepanier; C Sabapathy; P Chaudhury; A S Liberman; P Charlebois; B L Stein; L Lee Journal: Tech Coloproctol Date: 2018-12-19 Impact factor: 3.781
Authors: Eric J Ley; Carlos V R Brown; Ernest E Moore; Jack A Sava; Kimberly Peck; David J Ciesla; Jason L Sperry; Anne G Rizzo; Nelson G Rosen; Karen J Brasel; Rosemary Kozar; Kenji Inaba; Matthew J Martin Journal: J Trauma Acute Care Surg Date: 2020-11 Impact factor: 3.313
Authors: Rafael Rocha Tourinho-Barbosa; Marcos Tobias-Machado; Adalberto Castro-Alfaro; Gabriel Ogaya-Pinies; Xavier Cathelineau; Rafael Sanchez-Salas Journal: Arab J Urol Date: 2017-12-14